In this issue:
Survival with trastuzumab emtansine in residual HER2-positive breast cancer
Annual vs. less frequent mammographies at age ≥50 years after breast cancer
Endocrine therapy ± ribociclib in hormone receptor+, HER2– early breast cancer
HER2DX in HER2+ inflammatory breast cancer
First- to second-line attrition in metastatic breast cancer patients
Trastuzumab duocarmazine in pretreated HER2+ advanced/metastatic breast cancer
Outcomes and treatment patterns for stage I HER2+ breast cancer
Effects of tamoxifen on cognitive function in primary breast cancer
Quality-adjusted time without symptoms or toxicity analysis of DESTINY-Breast03
Antibody-drug radioconjugate for HER2+ trastuzumab-resistant xenografts
Please login below to download this issue (PDF)